Evaluate Vantage Homepage
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
Yesterday’s deal between GSK and Mersana threw the spotlight back on a forgotten oncology mechanism.
Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
Assets in oncology and psoriasis are set for upcoming Pdufa decisions.
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
But a surprise adcom for omecamtiv mecarbil might put a spanner in the works.
Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.